云南白药集团股份有限公司 投资者调研会议记录 时间：2023 年 11 月 9 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：安信证券-贺鑫、永赢基金-单林、华宝基金-魏扬帆 参加人员：董事会秘书-钱映辉、证券事务代表-赵雁、投资者关 系管理-杨可欣 会议内容 1、请介绍一下 2023 年三季度的经营情况。 答：2023 年前三季度，公司实现营业收入 296.89 亿元，同比增 长 10.30%；实现归母净利润 41.23 亿元，同比增长 78.90%；经营活 动产生的现金流量净额为 25.90 亿元，同比增长 33.33%；基本每股 收益年初至报告期末为 2.31 元/股，同比增长 50.98%；公司加权平 ...

云南白药集团股份有限公司 投资者调研会议记录表 编号：23-2311-01 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 ☑现场参观 □一对一沟通 □其他（走进上市公司） 安信证券-贺鑫 参与单位名称及人员 永赢基金-单林 姓名 华宝基金-魏扬帆 时间 2023年11月 9日 地点 集团总部办公大楼 董事会秘书-钱映辉、证券事务代表-赵雁、投资者关系管理- 上市公司接待人员 杨可欣 投资者关系活动主要 了解公司生产经营情况等相关问题 内容介绍 ...

股票代码：000538 股票简称：云南白药 公告编号：2023-43 云南白药集团股份有限公司 关于云南省国有股权运营管理有限公司继续引入 中国人寿资产管理有限公司增资的公告 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。本公司及其董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 云南省国有股权运营管理有限公司（以下简称"国有股权公司"） 持有云南白药集团股份有限公司（以下简称"公司"或 "云南白药"） 25.02%的股权，为公司并列第一大股东。 2022 年 6 月 15 日，公司披露了《关于云南省国有股权运营管理有 限公司引入中国人寿资产管理有限公司增资的公告》（公告编号：2022- 54），公司并列第一大股东国有股权公司的控股股东云南省投资控股集 团有限公司（以下简称"云投集团"）与中国人寿资产管理有限公司（以下 简称"中国人寿"）、国有股权公司于 2022 年 5 月 26 日签署了《云南 省国有股权运营管理有限公司增资协议》，协议约定由中国人寿向国有 股权公司增资，增资金额 90 亿元，增资前国有股权公司的股权结构为： 云投集团持股 10 ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2023 年 10 月 31 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：君合资本-周琳、穆瑶森 参加人员：董事会秘书-钱映辉、证券事务代表-赵雁、投资者关 系管理-杨可欣 会议内容 1、请介绍一下 2023 年三季度的经营情况。 答：2023 年前三季度，公司实现营业收入 296.89 亿元，同比增 长 10.3%；实现归母净利润 41.23 亿元，同比增长 78.9%；经营活动 产生的现金流量净额为 25.90 亿元，同比增长 33.33%；基本每股收 益年初至报告期末为 2.31 元/股，同比增长 50.98%；公司加权平均 ...

云南白药集团股份有限公司 投资者调研会议记录表 编号：22-2310-02 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（走进上市公司） 参与单位名称及人员 君合资本-周琳、穆瑶森 姓名 时间 2023年10 月31日 地点 集团总部办公大楼 董事会秘书-钱映辉、证券事务代表-赵雁、投资者关系管理- 上市公司接待人员 杨可欣 投资者关系活动主要 了解公司生产经营情况等相关问题 内容介绍 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 9,379,159,224.37, representing a 5.40% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 1,295,465,799.1, a significant increase of 61.05% compared to the same period last year[5]. - The net profit excluding non-recurring gains and losses for Q3 2023 was CNY 1,116,150,641.76, up by 6.28% year-over-year[5]. - The basic earnings per share for Q3 2023 was CNY 0.73, reflecting a 50.98% increase compared to the previous year[5]. - The net profit for the third quarter of 2023 was CNY 4,123,477,414.45, compared to CNY 2,304,896,295.31 in the same period last year, representing an increase of approximately 79%[26]. - Operating profit for the third quarter was CNY 4,873,377,249.69, up from CNY 2,536,852,034.54, indicating a growth of about 92% year-over-year[26]. - The total comprehensive income for the third quarter was CNY 4,094,749,621.00, compared to CNY 2,040,991,965.58 in the previous year, indicating an increase of about 100.5%[26]. - The basic earnings per share for the third quarter was CNY 2.31, compared to CNY 1.53 in the same period last year, representing an increase of approximately 50.3%[26]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was CNY 2,589,586,477.11, an increase of 33.33% compared to the same period last year[9]. - The company's cash and cash equivalents stood at CNY 2.76 billion, a decrease from CNY 3.01 billion in the previous quarter[24]. - The total cash and cash equivalents at the end of Q3 2023 amounted to 13,043,695,526.75 CNY, down from 18,886,986,484.32 CNY at the beginning of the period[29]. - The net cash flow from financing activities was negative at -3,131,138,555.76 CNY for Q3 2023, compared to -2,848,540,527.94 CNY in the same period last year[29]. - The cash received from loans was 901,453,995.03 CNY, a decrease from 1,970,254,254.26 CNY year-on-year[29]. - The cash paid for debt repayment was 1,208,474,903.38 CNY, compared to 1,928,728,367.68 CNY in the previous year[29]. - The company's inventory as of September 30, 2023, was CNY 6,922,510,026.53, down from CNY 7,993,207,044.26 at the beginning of the year[22]. - The total assets at the end of the reporting period were CNY 53,320,943,868.74, showing a slight increase of 0.02% from the end of the previous year[5]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 185,000[11]. - The largest shareholder, Yunnan State-owned Equity Operation Management Co., Ltd., holds 25.02% of shares, totaling 449,624,311 shares[11]. - The top ten shareholders hold a combined total of 1,000,000,000 shares, indicating significant ownership concentration[11]. - The company has no preferred shareholders as of the reporting period[13]. - The company repurchased 12,599,946 shares, representing 0.70% of total shares[12]. Strategic Initiatives - The company has initiated a smart technology business unit to enhance operational efficiency and innovation capabilities[15]. - The company appointed a new general manager for the smart technology business unit to drive digital strategy[15]. - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[25]. - The company actively focused on its core products and market expansion strategies to achieve growth in operating performance during the first half of 2023[19]. - The company plans to issue a total of CNY 30 billion in short-term financing bonds to optimize its financing structure and enhance liquidity[21]. Changes in Management and Plans - The company terminated the 2021 employee stock ownership plan, with 23,379,996 shares fully divested by May 26, 2023[14]. - A total of 6,772,080 stock options from the 2020 stock option incentive plan were canceled due to unmet performance targets[15]. - The company has updated several internal management systems, including investor relations and risk management[13]. - The company began implementing new accounting standards from the beginning of 2023[29]. Tax and Expenses - The income tax expense for Q3 2023 was CNY 741,257,264.53, an increase of 86.96% due to higher total profit[7]. - Research and development expenses increased to CNY 218.61 million, a rise of 5.4% from CNY 207.86 million in the previous year[25]. - Total operating costs amounted to CNY 25.66 billion, up 11.1% from CNY 23.10 billion year-on-year[25]. - The company reported a decrease in other comprehensive income, with a net amount of CNY -32,077,219.63 for the third quarter, compared to CNY -89,654,353.65 in the same period last year[26].

云南白药集团股份有限公司 投资者调研会议记录表 编号：21-2310-01 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（走进上市公司） 参与单位名称及人员 瑞银资管-Karianne Lancee、陈冰玉 姓名 时间 2023年10 月13日 地点 集团总部办公大楼 董事会秘书-钱映辉、证券事务代表-赵雁、投资者关系管理- 上市公司接待人员 杨可欣、董事会办公室工作人员-余璧玲、钱秋灵 投资者关系活动主要 了解公司ESG相关情况 内容介绍 ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2023 年 10 月 13 日 地点：集团总部办公大楼 召开方式：电话会议 投资者：瑞银资管-Karianne Lancee、陈冰玉 参加人员：董事会秘书-钱映辉、证券事务代表-赵雁、投资者关 系管理-杨可欣、董事会办公室工作人员-余璧玲、钱秋灵 会议内容 1、请介绍一下公司是如何保障女性员工权利的？ 答：公司密切关注女性员工，建设人性化管理体系，传达并落实 党和国家对女性劳动者的关怀和爱护，表达对女性劳动者的敬意。 2022 年公司女性员工人数为 4066 人，占员工总数的 46%。 云南白药积极参与《促进工作场所性别平等指导手册》公约的制 ...

股票代码：000538 股票简称：云南白药 公告编号：2023-41 云南白药集团股份有限公司 关于万隆控股更改公司名称、股份简称及相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"）于 2022 年 6 月 22 日 披露了《关于万隆控股集团有限公司相关事项的公告》（公告编号：2022- 55），如公司控股子公司万隆控股集团有限公司（以下简称"万隆控股"， 现已更名为"云白国际有限公司"）2022 年 1 月 21 日及 2021 年 11 月 19 日该等公告所载，万隆控股放贷业务（放贷业务由万隆财务有限公司经营） 的若干借款人已于还款方面违约。基于此，万隆控股董事会成立独立调查委 员会展开调查及出具报告，且可能延迟刊发 2021/2022 年全年业绩，同时， 应万隆控股要求，万隆控股的股份已于 2022 年 6 月 21 日上午 9 时正起在 香港联合交易所有限公司（以下简称"联交所"）暂停买卖，以待刊发（其中 包括）2021/2022 年全年业绩。 公司于 2022 年 7 月 2 日披露了《 ...

Financial Performance - Operating revenue for the first half of 2023 reached RMB 20,309,372,850.07, representing a 12.73% increase compared to RMB 18,016,738,609.15 in the same period last year[27]. - Net profit attributable to shareholders of the listed company was RMB 2,828,011,615.30, an increase of 88.47% from RMB 1,500,494,603.81 year-on-year[27]. - Net cash flows from operating activities increased by 91.18% to RMB 2,251,951,370.10, compared to RMB 1,177,950,057.27 in the previous year[27]. - Basic earnings per share rose to RMB 1.58, a 43.64% increase from RMB 1.10 in the same period last year[27]. - Total assets at the end of the reporting period were RMB 51,926,448,675.34, a decrease of 2.62% from RMB 53,320,943,868.74 at the end of the previous year[27]. - The net cash flow from operating activities was RMB 2.252 billion, up 91.18% YoY, and basic earnings per share increased by 43.64% to RMB 1.58[46]. - The Company maintained a weighted average return on equity of 7.17%, up 3.28 percentage points YoY[46]. - The company reported a significant increase in commercial sales revenue by RMB 1.76 billion during the reporting period[97]. - Income from industrial sales was RMB 7,498,960,250.10, accounting for 36.92% of total revenue, with a year-on-year growth of 7.77%[98]. - Income from commercial sales increased to RMB 12,771,903,564.67, which is 62.89% of total revenue, reflecting a year-on-year growth of 6.01%[99]. Business Segments - Yunnan Baiyao achieved operating revenue of RMB 20.309 billion in the first half of 2023, up 12.73% YoY, and a net profit attributable to shareholders of RMB 2.828 billion, up 88.47% YoY[46]. - The Pharmaceutical Business Group generated revenue of RMB 3.852 billion, marking a 14.63% increase YoY, with Yunnan Baiyao Aerosol contributing over RMB 900 million, an 18.20% YoY growth[48]. - The Health Products Business Group reported revenue of RMB 3.245 billion, a YoY increase of 0.81%, with Yunnan Baiyao toothpaste holding a 25% market share[51]. - The TCM Resources Business Group achieved external sales revenue of approximately RMB 879 million, a YoY increase of about 21%, with Panax notoginseng revenue increasing by 30%[54]. - Yunnan Pharma's revenue from principal businesses reached RMB 12.364 billion, a YoY increase of 13.6%, while logistics order-to-dispatch time decreased by 35.2% YoY[57][58]. Market Trends and Strategies - The pharmaceutical sector is experiencing a positive rebound, supported by economic improvements and favorable policies[34]. - The traditional Chinese medicine (TCM) sector benefits from national policies, enhancing growth opportunities in the OTC TCM market[35]. - E-commerce channels continue to dominate consumer product sales, while traditional channels are declining[36]. - The company emphasizes the need for refined management and deeper consumer insights to maintain competitiveness in a challenging market[37]. - The Company has launched 23 online stores as part of its omnichannel marketing strategy, focusing on e-commerce[62]. - The company is transitioning from a traditional manufacturing enterprise to a provider of comprehensive solutions, leveraging big data and digitalization[77]. Research and Development - The Company invested RMB 145 million in R&D during the reporting period, representing a 12.59% year-over-year increase[70]. - R&D investment increased by 12.59% to RMB 144.82 million, reflecting the company's commitment to innovation and product development[97]. - The company has consistently increased its investment in drug R&D to maintain technological advantages and enhance core competitiveness[131]. Environmental and Social Responsibility - Yunnan Baiyao was included in the List of "Top 100 ESG Listed Companies in China" in the first half of 2023, reflecting its commitment to social responsibility and sustainable development[155]. - The Company complied with various environmental protection laws and regulations, implementing management policies for environmental protection[148]. - The total emissions of nitrogen oxide were reported at 96.64 mg/m³, below the standard limit of 400 mg/m³[150]. - The Company reported a total of 4.54 tons of COD emissions in wastewater, which is compliant with the standard limit of 500 mg/L[150]. - The Company has implemented measures to manage hazardous waste and ensure compliance with environmental standards[149]. - Yunnan Baiyao has established a gene bank for genuine traditional Chinese medicine and invested in protecting endangered species, contributing to biodiversity conservation[157]. - Yunnan Baiyao actively engages in community support initiatives, including targeted assistance to rural areas to prevent poverty[158]. Corporate Governance and Compliance - The company has committed to maintaining independence in its operations, ensuring no conflicts of interest with its controlling shareholders[169]. - Yunnan Baiyao Group reported a commitment to maintain independence from related parties, ensuring no illegal occupation of funds and assets[171]. - The company aims to minimize related party transactions and ensure fair pricing based on market principles[171]. - The company has undertaken to compensate for any losses incurred due to violations of commitments regarding related party transactions[172]. - The company has committed to fulfilling all obligations related to asset restructuring and maintaining operational independence[174]. - The company has pledged to link future compensation systems to the implementation of compensatory measures[186].